General Information
As of 05/25/2012
|
| NAV |
$9.49 |
| NAV Daily Change |
$0.03 |
| % Yield |
0 |
| % SEC Yield |
N/A |
| % YTD Return (as of 04/30/2012) |
12.05 |
| Objective* |
Equity - Sector Health |
| Peer* |
HL LG |
* Key
Portfolio Statistics
|
| % Unrealized Gain YTD |
13.98 |
| Net Assets (Mil $) N/A |
666.77 |
| % Turnover N/A |
64.00 |
Fees
|
| % Max Sales Load |
5.75 |
| % Min Sales Load |
.00 |
| % Max Deferred Load |
.00 |
Expenses
|
| % Max 12b-1 Fee |
.25 |
| % Max Management Fee |
1.24 |
| % Redemption Fee |
.00 |
| % Expense Ratio |
1.56 |
Allocation
|
| Large Growth |
.00 |
| Large Value |
.00 |
| Small Growth |
35.67 |
| Small Value |
.00 |
| Foreign Stock |
14.08 |
| Emerging Market |
.00 |
| Precious Metals |
.00 |
| Intermediate Bond |
23.47 |
| Foreign Bond |
.00 |
| High Yield Bond |
.00 |
Portfolio Information |
| Composition |
| As of N/A |
% of Net Assets |
| Stock |
97.53 |
| Cash |
2.06 |
| Bonds |
.00 |
| Preferred |
.00 |
| Convertibles |
.00 |
| Foreign Stock |
34.31 |
| Foreign Bonds |
.00 |
| Hedge |
.00 |
| Other |
.41 |
Sector / Country Weightings
|
| As of 02/29/2012 |
% of Portfolio |
| Health |
58.50 |
| Industrial Cyclical |
14.02 |
| Finance |
9.09 |
| Services |
8.34 |
| Other |
5.46 |
| Retail Trade |
3.13 |
| Technology |
1.46 |
| N/A |
N/A |
| N/A |
N/A |
Portfolio Holdings |
Top Equity Holdings
(As of 02/29/2012) |
% of Portfolio |
Value (Mil$) |
|
| PFIZER INC |
6.82 |
68.11 |
| ROCHE HOLDING AG |
5.63 |
56.22 |
| NOVARTIS AG ADR |
4.68 |
46.76 |
| BRISTOL MYERS SQUIBB CO |
4.57 |
45.68 |
| SANOFI ADR |
4.21 |
42.11 |
| MERCK + CO. INC. |
4.15 |
41.42 |
| MITSUBISHI TANABE PHARMA CORP |
4.10 |
40.98 |
| SAWAI PHARMACEUTICAL |
3.07 |
30.69 |
| WATSON PHARMACEUTICALS INC |
3.06 |
30.60 |
| N/A |
N/A |
N/A |
|
|
This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Funds over the next 6 months.
| Zacks Rank |
Definition |
| #1 |
Strong Buy |
| #2 |
Buy |
| #3 |
Hold |
| #4 |
Sell |
| #5 |
Strong Sell |
| S&P |
500 |
Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Zacks Premium Research
|
Zacks Mutual Fund Rank
|
| |
Find similar funds that have a Mutual Fund Rank.
Find Similar Funds Now  |
Fund Description
|
The fund was incepted in July 1985 and is managed by Boston Management and Research. The objective of the fund is to seek long-term capital growth by investing in a global and diversified portfolio of health sciences companies. The fund pursues its objective by investing in worldwide health sciences portfolio. The fund invests primarily in common stocks of companies engaged in the development, production or distribution of products related to scientific advances in health care and companies with a broad range of market capitalization's, including small companies. The fund offers dividends and capital gains annually.
|
Zacks Commentary for ETHSX
|
|
|
|
Stock Holding Statistics
% of Net Assets
|
| As Of |
N/A |
| Total Issues |
52 |
| Avg. P/E |
25.73 |
| Avg. P/Book |
5.26 |
| Avg. EPS Growth |
12.34 |
| Avg. Market Value (Mil $) |
53,595 |
Risk
|
|
3 Year |
5 Year |
10 Year |
| Beta |
0.60 |
0.59 |
0.64 |
| Alpha |
3.80 |
4.08 |
2.36 |
| R Squared |
0.57 |
0.49 |
0.48 |
| Std. Dev. |
12.51 |
16.04 |
14.68 |
| Sharpe |
1.30 |
0.28 |
3.00 |
Shareholder Information
|
| Manager |
Team Managed |
| Since |
N/A |
| Manager Rating * SEE EXPLANTION |
N/A |
| Inception Date |
07/26/1985 |
| Shareholders |
43,033 |
| Dividends Paid |
A |
| Minimum Initial Investment |
$1,000 |
| Minimum Subsequent Investment |
$0 |
| IRA Minimum |
$0 |
| IRA Available |
Y |
Check Writing |
N |
Phone Invest |
Y |
| Phone Exchange |
Y |
Phone Redeem |
Y |
Auto Invest |
Y |
| Wire Redeem |
Y |
Wire Fee |
Y |
Wire Transfer |
Y |
Contact Information
|
| Family |
Eaton Vance |
| Address |
The Eaton Vance Bldg, 255 State St
Boston, MA 02109 |
| Phone |
800 262-1122 |
|
Sponsored Links 
